Drug
Quizartinib clinical trials
Also written AC220, Vanflyta and AC010220.
- studies test it
- 38
- open now
- 9
- in phase 3
- 5
- first study started
- 2007
Keep track of what changes. Save the quizartinib studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Brand
Studies by the year they started
38 studies that test it; most in 2020 (6)
| Year | Studies |
|---|---|
| 2007 | 1 |
| 2011 | 2 |
| 2012 | 2 |
| 2013 | 1 |
| 2014 | 1 |
| 2016 | 4 |
| 2017 | 1 |
| 2018 | 4 |
| 2019 | 4 |
| 2020 | 6 |
| 2021 | 1 |
| 2022 | 1 |
| 2023 | 1 |
| 2024 | 6 |
| 2025 | 2 |
| 2026 | 1 |
By phase
A phase 1/2 study counts in both.
- Early Phase 1
- 1
- Phase 1
- 24
- Phase 2
- 17
- Phase 3
- 5
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 22 · Other 16
Daiichi Sankyo (15) · M.D. Anderson Cancer Center (7) · Daiichi Sankyo Co., Ltd. (6) · PETHEMA Foundation (3) · Cardiff University (1) · National Cancer Institute (NCI) (1) · Kura Oncology, Inc. (1) · Princess Maxima Center for Pediatric Oncology (1)
Often tested with
Tested in the same studies.
Azacitidine (4) · Cytarabine (4) · Venetoclax (4) · CPX-351 (3) · Daunorubicin (2) · Rufinamide (1) · Efavirenz (1) · Dabigatran (1)
Studies
Open first, then newest update. How each study uses quizartinib is read from its arms, and is right about nine times in ten.
Testing it · 38
- MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)RecruitingPhase 2National Cancer Institute (NCI)NCT05564390Written as Quizartinib
- Azacytidine, Venetoclax Plus Minus Quizartinib for First Line Older/Unfit AML Patients (VENP-A-QUI)RecruitingPhase 3PETHEMA FoundationNCT07478991Written as Quizartinib
- Quizartinib, Decitabine, and Venetoclax in Treating Participants With Untreated or Relapsed Acute Myeloid Leukemia or High Risk Myelodysplastic SyndromeRecruitingPhase 1/2M.D. Anderson Cancer CenterNCT03661307Written as Quizartinib
- Dose Escalation and Expansion of Ziftomenib in Combination With Quizartinib in Acute Myeloid LeukemiaRecruitingPhase 1M.D. Anderson Cancer CenterNCT06769490Written as Quizartinib
- Evaluation of Two Dose Levels of Quizartinib as Maintenance in FLT3-ITD (+) Acute Myeloid Leukemia Patients in Complete RemissionRecruitingPhase 2Daiichi SankyoNCT06824168Written as Quizartinib High Dose
- Cladribine, Idarubicin, Cytarabine, and Quizartinib in Treating Patients With Newly Diagnosed, Relapsed, or Refractory Acute Myeloid Leukemia or High-Risk Myelodysplastic SyndromeRecruitingPhase 1/2M.D. Anderson Cancer CenterNCT04047641Written as Quizartinib
- Assessment of Quizartinib Pharmacokinetic in Subjects With Severe Hepatic ImpairmentRecruitingPhase 1Daiichi SankyoNCT06740799Written as Quizartinib
- A Study to Investigate the Safety and Tolerability of Ziftomenib in Combination With Venetoclax/Azacitidine, Venetoclax, 7+3, or 7+3+Quizartinib in Patients With AMLRecruitingPhase 1Kura Oncology, Inc.NCT05735184Written as Quizartinib
- CHIP-AML22/Quizartinib: Quizartinib + Chemotherapy in Newly Diagnosed Pediatric FLT3-ITD+ and NPM1wt AML PatientsRecruitingPhase 2Princess Maxima Center for Pediatric OncologyNCT06262438Written as Quizartinib
- Quizartinib With Azacitidine or Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic SyndromeCompletedPhase 1/2M.D. Anderson Cancer CenterNCT01892371Written as Quizartinib
- Azacitidine and Quizartinib for the Treatment of Myelodysplastic Syndrome or Myelodysplastic/Myeloproliferative Neoplasm With FLT3 or CBL MutationsActive, not recruitingPhase 1/2M.D. Anderson Cancer CenterNCT04493138Written as Quizartinib
- Quizartinib or Placebo Plus Chemotherapy in Newly Diagnosed Patients With FLT3-ITD Negative AMLActive, not recruitingPhase 3Daiichi SankyoNCT06578247Written as Quizartinib
- Liposomal Cytarabine and Daunorubicin (CPX-351) and Quizartinib for the Treatment of Acute Myeloid Leukemia and High Risk Myelodysplastic SyndromeActive, not recruitingPhase 1/2M.D. Anderson Cancer CenterNCT04128748Written as Quizartinib
- Safety and Efficacy of Quizartinib in Children and Young Adults With Acute Myeloid Leukemia (AML), a Cancer of the BloodActive, not recruitingPhase 1/2Daiichi SankyoNCT03793478Written as Quizartinib
- Trial to Compare Efficacy and Safety of Chemotherapy/Quizartinib vs Chemotherapy/Placebo in Adults FMS-like Tyrosine Kinase 3 (FLT3) Wild-type Acute Myeloid Leukemia (AML)CompletedPhase 2PETHEMA FoundationNCT04107727Written as Quizartinib
- A Study to Evaluate QTc Prolongation With Quizartinib in Healthy Subjects Under Rapid Acceleration of Heart RateCompletedPhase 1Daiichi SankyoNCT06772246Written as Quizartinib
- Study of Quizartinib in Japanese Patients With Newly Diagnosed Acute Myeloid Leukemia (AML)CompletedPhase 1Daiichi Sankyo Co., Ltd.NCT02834390Written as Quizartinib
- Study to Assess the Effect of a CYP3A Weak Inducer Rufinamide on Quizartinib Pharmacokinetics in Healthy SubjectsCompletedPhase 1Daiichi SankyoNCT06740825Written as Quizartinib
- Venetoclax and Quizartinib in Treating Patients With FLT3-mutated Recurrent or Refractory Acute Myeloid LeukemiaTerminatedPhase 1/2M.D. Anderson Cancer CenterNCT03735875Written as Quizartinib
- Quizartinib With Standard of Care Chemotherapy and as Continuation Therapy in Patients With Newly Diagnosed FLT3-ITD (+) Acute Myeloid Leukemia (AML)CompletedPhase 3Daiichi SankyoNCT02668653Written as Quizartinib
See all 38 studies that test quizartinib →
Given in every arm · 4 — quizartinib is usual care beside what is tested
- Testing the Investigational Medication Combination of Azacitidine, Venetoclax, and Quizartinib Compared to the Usual Treatment of Cytarabine, Daunorubicin, and Quizartinib for Patients With FLT3-ITD Mutant Acute Myeloid Leukemia (A MyeloMATCH Treatment Trial)Not yet recruitingPhase 2National Cancer Institute (NCI)NCT07862517Written as Quizartinib
- Study of SA+X in the Treatment of Newly Diagnosed AMLRecruitingPhase 2Ruijin HospitalNCT07548710Written as Quizartinib Dihydrochloride
- Clinical Trial to Assess the Safety and Tolerability of the Combination of Low-dose Cytarabine or Azacitidine Plus Venetoclax and Quizartinib in Newly Diagnosed AML Patients Aged Equal or More Than 60 Years OldCompletedPhase 1/2PETHEMA FoundationNCT04687761Written as Quizartinib
- AC220 for Children With Relapsed/Refractory ALL or AMLCompletedPhase 1Therapeutic Advances in Childhood Leukemia ConsortiumNCT01411267Written as AC220
Codes
What other systems call quizartinib · ClinicalTrials.gg INT005514
- MeSH (NLM) C544967quizartinibConfirmed ClinicalTrials.gov, NLM
- UNII (FDA) 7LA4O6Q0D3QUIZARTINIBConfirmed FDA, NLM, Wikidata
- Wikidata Q7272714quizartinibConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C68936QuizartinibOne source FDA
- DrugBank DB12874One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C544967 | quizartinib | Confirmed ClinicalTrials.gov, NLM |
| UNII (FDA) | 7LA4O6Q0D3 | QUIZARTINIB | Confirmed FDA, NLM, Wikidata |
| Wikidata | Q7272714 | quizartinib | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C68936 | Quizartinib | One source FDA |
| DrugBank | DB12874 | — | One source Wikidata |
Also registered as quizartinib dihydrochloride (UNII WK7Q6ZIZ10).
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.